Patent · US Active

2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor

US11478474B2 · kind B2 · utility

1Cited by

0References

15Claims

0Family size

Assignee

HUTCHISON MEDIPHARMA LIMITED · CN

Inventors

Guangxiu Dai · Shanghai, CN
Kun Xiao · Shanghai, CN

Key dates

Filing date	Oct 20, 2021
Grant date	Oct 25, 2022
Priority date	—
Expiry date	Oct 20, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to heteroaryl heterocyclic compounds, e.g., the compound of the formula shown below, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.